이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

VYNE Therapeutics 배당금

배당금 기준 확인 0/6

VYNE Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.97
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

Apr 27

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

May 04

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10

VYNE Therapeutics closes capital raise of $50M

Jan 29

What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?

Jan 06

VYNE Therapeutics reports successful FDA meeting for FCD105 in acne

Dec 17

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 VYNE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: VYNE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

VYNE Therapeutics 시장 대비 배당 수익률

VYNE 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (VYNE)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Pharmaceuticals)	2.2%
3년 후 애널리스트 예측 (VYNE)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VYNE 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VYNE 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VYNE 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: VYNE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

VYNE Therapeutics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics Inc. Announces Results from Its Phase 2a Trial of FMX114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$5.80

High number of new and inexperienced directors

VYNE Therapeutics Inc. Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an in Vivo Model of Rheumatoid Arthritis

Consensus forecasts updated

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Lead Bet Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for the Treatment of Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Price target increased to US$5.80

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.59 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$4.83 loss in 2Q 2020)

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics Inc. Announces Approval of Amzeeq (Minocycline) and Zilxi (Minocycline) in Chinese Economic Pilot Zone

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

Vyne Therapeutics Receives A Paragraph IV Certification Notice from Perrigo Israel Pharmaceuticals Advising That Perrigo Has Submitted to the FDA

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE Therapeutics Inc.(NasdaqGS:VYNE) dropped from Russell 2000 Dynamic Index

Forecast breakeven pushed back to 2024

CFO & Treasurer Andrew Saik has left the company

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Price target decreased to US$12.71

First quarter 2021 earnings released: US$0.42 loss per share (vs US$3.79 loss in 1Q 2020)

Director recently bought US$93k worth of stock

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$7.88 loss per share (vs US$6.65 loss in FY 2019)

Analysts update estimates

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts